ReviewEndocrine reviews2024
Protective Factors and the Pathogenesis of Complications in Diabetes.
Review in Endocrine reviews, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
115 citing papers in PubMed, 2 syntheses or guidelines pooled it, 208 citations in OpenAlex.
- The effects of non-insulin anti-diabetic medications on the diabetic microvascular complications: a systematic review and meta-analysis of randomized clinical trials.BMC endocrine disorders · 2025Pooled it
- Diabetes Driven Oncogenesis and Anticancer Potential of Repurposed Antidiabetic Drug: A Systemic Review.Cell biochemistry and biophysics · 2024Pooled it
- The effects of vildagliptin on glycemic variability in patients with type 2 diabetes on premixed insulin therapy.Frontiers in endocrinology · 2025Trial
- DMBT1 in Adipose-Derived Stem Cell-Derived Exosomes Participates in Alleviating Ferroptosis to Promote Diabetic Wound Healing.Stem cell reviews and reports · 2026Article
- Impact of Complicated Diabetes Mellitus in Patients Following Severe Traumatic Brain Injury.Neurocritical care · 2026Article
- Article
- Targeted proteomics of extreme vascular phenotypes in type 1 diabetes: the ESCAPER study.Cardiovascular diabetology · 2026Article
- Modulatory Activity of Uncaria tomentosa Extract in the Expression of Proteins Involved in the Unfolded Protein Response and Insulin Resistance.Current issues in molecular biology · 2026Article
- Sex-Specific Associations of Inflammatory Biomarkers With All-Cause and Cardiovascular Mortality Across Glycaemic Status: A Prospective UK Biobank Study.Diabetes, obesity & metabolism · 2026Article
- Prognostic value of advanced imaging biomarkers for the progression of diabetic retinopathy: a systematic review.Diabetology & metabolic syndrome · 2026Article
- Resilience to Diabetic Retinopathy (RDR) Is Associated with a Pre-Retinopathy Transcriptional Program Induced by Diabetes.Biomolecules · 2026Article
- Environmentally activatable hydrogel for spatiotemporally programmed nitric oxide delivery for diabetic wound healing.Materials today. Bio · 2026Article
- The progress and challenges of mesenchymal stromal cell-based therapy for diabetes and its complications.Biological research · 2026Review
- Two Patients With Extremely Long Type 1 Diabetes Duration With Very Few Complications and Remaining Insulin Secretion.Clinical case reports · 2026Article
- From the energy factory to the intercellular communication medium: the emerging role of intercellular mitochondrial transfer and mitochondrial transplantation therapy in diabetes and diabetic complications.Journal of translational medicine · 2026Review
- The diagnostic value of CXCL8 in diabetes mellitus co-morbidity with tuberculosis.BMC infectious diseases · 2026Article
- Translation and Psychometric Evaluation of the Diabetes Self-Management Questionnaire in Hebrew (H-DSMQ) for Adults With Type 2 Diabetes in Israel.Research in nursing & health · 2026Article
- Diabetic Retinopathy Screening in Primary Care Real Practice: Study Procedures and Baseline Characteristics from the RETINAvalid Project.Healthcare (Basel, Switzerland) · 2026Article
- Diabetes and its complications: molecular mechanisms, prevention and treatment.Signal transduction and targeted therapy · 2026Review
- Article
55 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
Abstract
Chronic complications of diabetes are due to myriad disorders of numerous metabolic pathways that are responsible for most of the morbidity and mortality associated with the disease. Traditionally, diabetes complications are divided into those of microvascular and macrovascular origin. We suggest revising this antiquated classification into diabetes complications of vascular, parenchymal, and hybrid (both vascular and parenchymal) tissue origin, since the profile of diabetes complications ranges from those involving only vascular tissues to those involving mostly parenchymal organs. A major paradigm shift has occurred in recent years regarding the pathogenesis of diabetes complications, in which the focus has shifted from studies on risks to those on the interplay between risk and protective factors. While risk factors are clearly important for the development of chronic complications in diabetes, recent studies have established that protective factors are equally significant in modulating the development and severity of diabetes complications. These protective responses may help explain the differential severity of complications, and even the lack of pathologies, in some tissues. Nevertheless, despite the growing number of studies on this field, comprehensive reviews on protective factors and their mechanisms of action are not available. This review thus focused on the clinical, biochemical, and molecular mechanisms that support the idea of endogenous protective factors, and their roles in the initiation and progression of chronic complications in diabetes. In addition, this review also aimed to identify the main needs of this field for future studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.